STATICIN Drug Patent Profile
Which patents cover Staticin, and when can generic versions of Staticin launch?
Staticin is a drug marketed by Westwood Squibb and is included in one NDA.
The generic ingredient in STATICIN is erythromycin. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Staticin
A generic version of STATICIN was approved as erythromycin by TORRENT on July 6th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for STATICIN?
- What are the global sales for STATICIN?
- What is Average Wholesale Price for STATICIN?
Summary for STATICIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 61 |
| Patent Applications: | 3,771 |
| DailyMed Link: | STATICIN at DailyMed |
US Patents and Regulatory Information for STATICIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Westwood Squibb | STATICIN | erythromycin | SOLUTION;TOPICAL | 050526-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
